Thera-SAbDab

VARLILUMAB

>   Structural Summary
TherapeuticVarlilumab
TargetCD27
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedCelldex Therapeutics Inc, Oncothyreon, University of California at San Francisco, University of Virginia
Conditions Approvedna
Conditions ActiveMalignant melanoma, Solid tumours, Non-Hodgkin's lymphoma, Renal cell carcinoma, Glioma
Conditions DiscontinuedHaematological malignancies, Prostate cancer, Breast cancer, Ovarian cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]